Waycaster Curtis, Carter Marissa J, Gilligan Adrienne M, Mearns Elizabeth S, Fife Caroline E, Milne Catherine T
Smith & Nephew, Fort Worth, TX 76109, USA.
Strategic Solutions, Inc., Cody, WY 82414, USA.
J Comp Eff Res. 2018 Feb;7(2):149-165. doi: 10.2217/cer-2017-0066. Epub 2017 Oct 27.
Chronic dermal ulcers affect approximately 2.4-4.5 million people in the USA and are associated with loss of function, decreased quality of life and significant economic burden. Debridement is a critical component of wound care involving removal of nonviable tissue from chronic wounds to stimulate the granulation and epithelialization process. Clostridial collagenase ointment has been used as a method of wound debridement for more than 50 years and is currently the only enzymatic debriding ointment with US FDA approval. This review discusses the results of recent real-world studies that build upon the evidence demonstrating the clinical effectiveness, cost-effectiveness and safety of clostridial collagenase ointment across wound types and care settings.
在美国,慢性皮肤溃疡影响着约240万至450万人,与功能丧失、生活质量下降以及巨大的经济负担相关。清创术是伤口护理的关键组成部分,包括从慢性伤口中清除坏死组织,以刺激肉芽形成和上皮形成过程。梭菌胶原酶软膏作为一种伤口清创方法已使用了50多年,是目前唯一获得美国食品药品监督管理局批准的酶促清创软膏。本综述讨论了近期实际研究的结果,这些研究以相关证据为基础,证明了梭菌胶原酶软膏在各种伤口类型和护理环境中的临床有效性、成本效益和安全性。